期刊
DIABETES
卷 61, 期 12, 页码 3285-3293出版社
AMER DIABETES ASSOC
DOI: 10.2337/db12-0117
关键词
-
资金
- Natural Science Foundation of China/Research Grants Council of Hong Kong Joint Research Scheme [N_CUHK428/09]
- National Science Foundation of China [30890041, 30931160434]
- Ministry of Science and Technology of China (973 programs) [2010CB912502, 2012CB517805]
- Hong Kong General Research Fund [2140676, 465611]
Recent evidence highlights the therapeutic potential of peroxisome proliferator-activated receptor-delta (PPAR delta) agonists to increase insulin sensitivity hi diabetes. However, the role of PPAR delta in regulating vascular function is incompletely characterized. We investigate whether PPAR delta activation improves endothelial function in diabetic and obese mice. PPAR delta knockout (KO) and wild-type (WT) mice fed with high-fat diet and db/db mice were used as diabetic mouse models, compared with PPAR delta KO and WT mice on normal diet and db/m(+) mice. Endothelium-dependent relaxation (EDR) was measured by wire myograph. Flow-mediated vasodilatation (FMD) was measured by pressure myograph. Nitric oxide (NO) production was examined in primary endothelial cells from mouse aortae. PPAR delta agonist GW1516 restored EDRs in mouse aortae under high-glucose conditions or in db/db mouse aortae ex vivo. After oral treatment with GW1516, EDRs in aortae and FMDs in mesenteric resistance arteries were improved in obese mice in a PPAR delta-specific manner. The effects of GW1516 on endothelial function were mediated through phosphatidylinositol 3-kinase (PI3K) and Ala with a subsequent increase of endothelial nitric oxide synthase (eNOS) activity and NO production. The current study demonstrates an endothelial-protective effect of PPAR delta agonists in diabetic mice through PI3K/Akt/eNOS signaling, suggesting the therapeutic potential of PPAR delta agonists for diabetic vasculopathy. Diabetes 61:3285-3293, 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据